ARCHIVES

Two-Month Survival Benefit For Some NSCLC Patients

This article is from The Cancer Letter archive.

Vol. 25 No. 5 | May 31, 2002

Download PDF Visit The Full Archive

Related Articles

Pastan’s Laboratory Creates “Chimeric” Monoclonal Antibody With Human, Muse

August 12, 1988

CMS, FDA Developing Process For Concurrent Therapy ApprovalsAACI To Honor Mary-Claire King, Sen. Sherrod Brown

October 1, 2010

FDA Approves Iressa For Third-Line Treatment Of Non-Small Cell Lung Cancer

May 9, 2003

Continuing Resolution Funds Agencies Through Dec. 5.

November 17, 2000

Trials Approved by NCI CTEP For The Month of February

February 24, 2012

NCI To Recomplete CIDAC Contracts

September 23, 1977